• sv
Contact
  • About us

    About us

    Orexo is a fully integrated specialty pharmaceutical company

     

    • CEO comments
    • Objectives & Strategies
    • Key market
    • Financial information
    • Board of Directors & Management
    • Corporate Governance
    • Career
    • Meet us
    • History
  • Key Therapeutic Area

    Key Therapeutic Area

    Opioid addiction is a treatable chronic disease

  • Products

    Products

    Developed 4 products approved worldwide

    • Zubsolv®
    • Abstral®
    • Edluar®
  • Pipeline

    Pipeline

    Embracing all aspects of opioid addiction

    • Innovation
    • Technologies
    • OX124 Opioid overdose
    • OX125 Opioid overdose
    • OX338 Acute moderate to severe pain
    • OX382 Opioid dependence
    • OX-MPI Microvasular disease
    • OXD01 Opioid Use Disorder
    • OXD02 Alcohol Use Disorder
  • Sustainability

    Sustainability

    We will be recognized for the added value our products bring to patients and societies

    • Our team
    • People and society
    • Opioidcrisis
    • Our commitments
  • Investors

    Investors

    Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.

    • Financial calendar & events
    • Press releases
    • News
    • Reports, presentations and audiocasts
    • Analysts
    • Subscription
    • The share
    • Value Drivers
    • Key market
    • Financial information & key figures
    • Prospectus
    • IR contact
  • Media

    Media

    Follow Orexo in social media

    • Press releases
    • News
    • Social media
    • Image bank
    • Press contact
  • Orexo
  • Media
  • News
Top image

News

Show:
  • Latest 6 months
  • 2019
  • 2018
  • 2017
  • 2016
Loading...
  • Save the date: Orexo to host Capital Markets Day focusing on Digital Health, on March 17, 2020
    Dec 3 2019
  • Orexo appoints Dennis Urbaniak as Executive Vice President Digital Health
    Dec 2 2019
  • Orexo to Present at Jefferies 2019 Healthcare Conference
    Nov 8 2019
  • Invitation to presentation of Orexo´s Q3 2019 Interim Report, on October 24
    Oct 16 2019
  • Orexo´s Nomination Committee for the Annual General Meeting 2020
    Oct 14 2019
  • Orexo signs partnership agreement with GAIA to develop and commercialize a new digital therapy for the treatment of Opioid Use Disorder
    Aug 20 2019
  • Orexo signs license and supply agreement with Mundipharma for Zubsolv® in Australia and New Zealand
    Jul 10 2019
  • Orexo prepays part of the corporate bond loan
    Jul 9 2019
  • 1
  • 2

Our drug delivery technologies improve pharmaceuticals

 

P.O. Box 303. SE-751 05 Uppsala, Sweden

Tel. +46 (0)18 780 88 00

info@orexo.com

 

©2019

Orexo AB (publ.) – All rights reserved

Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy Orexo US

This website intends to use cookies to improve the website and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information, Read more

Accept
Disclaimer
Return Continue